Species of sphingolipids have been associated with prediabetes risk. Dr Samuel Dagogo-Jack (University of Tennessee Health Science Center, Memphis, TN, USA) discusses the outcome of a longitudinal study conducted at the University of Tennessee which followed a diverse cohort of patients who initially presented with ‘normal’ glucose metabolism but bifurcated into two subgroups: those with ‘normal’ glucose levels (‘non-progressors’) and those who have progressed to prediabetes (‘progressors’).
The abstract ‘Association of Ceramide and Sphingolipid Species with Incident Prediabetes among Offspring of Parents with Type 2 Diabetes’ was presented at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
- Your study determined the association between sphingolipids and prediabetes risk – please can you outline the study design and key findings? (0:41)
- Why was it important to include a diverse cohort of patients? (10:14)
Disclosures: Samuel Dagogo-Jack has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
Share this Video
Related Videos In Diabetes
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Carol Levy, DTM 2022: The use of Control-IQ technology in prior MDI and basal-only insulin users with type 2 diabetes
In this touchENDOCRINOLOGY interview, Prof. Carol Levy (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) discusses her study which evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology to show that Control-IQ technology could offer considerable benefit to individuals with type 2 diabetes. The abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!